drugset / Trial / NCT01972841

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841

Phase 3 Completed 3527 enrolled Astellas Pharma Europe B.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.

Timeline

Start
2013-11-05
Primary completion
2015-10-22
Completion
2015-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 25 mg Oral
Subject Mirabegron Other / unclassified 50 mg Oral
Subject Solifenacin Small molecule 5 mg Oral

Indications